| Symbol | CRVS |
|---|---|
| Name | CORVUS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 901 GATEWAY BOULEVARD,THIRD FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 900-4520 |
| Fax | — |
| — | |
| Website | https://www.corvuspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001626971 |
| Description | Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The companys lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant. Additional info from NASDAQ: |
(30% Negative) CORVUS PHARMACEUTICALS, INC. (CRVS) Reports Q2 2026 Financial Results
Read moreNew Form S-8 - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001104659-26-057263 <b>Size:</b> 228 KB
Read moreChan Andrew C. 🟢 acquired 30.0K shares (1 derivative) of Corvus Pharmaceuticals, Inc. (CRVS) at $16.02 Transaction Date: Apr 23, 2026 | Filing ID: 000149
Read moreNew Form 3 - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001610717-26-000148 <b>Size:</b> 9 KB
Read moreNew Form DEFA14A - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048600 <b>Size:</b> 454 KB
Read moreCorvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
Read moreCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Read more(99% Neutral) CORVUS PHARMACEUTICALS, INC. (CRVS) Announces Business Combination
Read moreNew Form 424B5 - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001104659-26-027382 <b>Size:</b> 527 KB
Read moreNew Form S-3ASR - Corvus Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-13 <b>AccNo:</b> 0001104659-26-027362 <b>Size:</b> 906 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Phase2 | Atopic Dermatitis | Recruiting | 2026-02-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Phase2 | Atopic Dermatitis | Recruiting | 2026-02-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT07310901 | A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Effi… | Phase1 | Obese But Otherwise Healthy Participants | Recruiting | 2025-12-04 | 2026-07-31 | ClinicalTrials.gov |
| NCT07310901 | A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Effi… | Phase1 | Obese But Otherwise Healthy Participants | Recruiting | 2025-12-04 | 2026-07-31 | ClinicalTrials.gov |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase1 | Solid Tumor | Recruiting | 2024-12-04 | 2026-12-01 | ClinicalTrials.gov |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase1 | Solid Tumor | Recruiting | 2024-12-04 | 2026-12-01 | ClinicalTrials.gov |
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Perip… | Phase3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recruiting | 2024-10-02 | 2028-12-01 | ClinicalTrials.gov |
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Perip… | Phase3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recruiting | 2024-10-02 | 2028-12-01 | ClinicalTrials.gov |
| NCT06345404 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants … | Phase1 | Atopic Dermatitis | Completed | 2024-04-16 | 2026-02-24 | ClinicalTrials.gov |
| NCT06345404 | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants … | Phase1 | Atopic Dermatitis | Completed | 2024-04-16 | 2026-02-24 | ClinicalTrials.gov |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-04-01 | 2027-01-27 | ClinicalTrials.gov |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-04-01 | 2027-01-27 | ClinicalTrials.gov |
| NCT04734873 | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to M… | Phase3 | Covid-19 | Terminated | 2021-02-25 | 2021-08-18 | ClinicalTrials.gov |
| NCT04734873 | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to M… | Phase3 | Covid-19 | Terminated | 2021-02-25 | 2021-08-18 | ClinicalTrials.gov |
| NCT04464395 | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | Phase1 | COVID-19 | Completed | 2020-07-01 | 2021-07-09 | ClinicalTrials.gov |
| NCT04464395 | Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | Phase1 | COVID-19 | Completed | 2020-07-01 | 2021-07-09 | ClinicalTrials.gov |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed… | Phase1 | Multiple Myeloma | Completed | 2020-02-20 | 2022-03-01 | ClinicalTrials.gov |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed… | Phase1 | Multiple Myeloma | Completed | 2020-02-20 | 2022-03-01 | ClinicalTrials.gov |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lympho… | Phase1 | T-cell Lymphoma | Active_Not_Recruiting | 2019-05-03 | 2026-04-30 | ClinicalTrials.gov |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lympho… | Phase1 | T-cell Lymphoma | Active_Not_Recruiting | 2019-05-03 | 2026-04-30 | ClinicalTrials.gov |
| NCT03813160 | Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | Phase3 | Dermatomyositis | Completed | 2018-12-17 | 2021-10-05 | ClinicalTrials.gov |
| NCT03813160 | Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | Phase3 | Dermatomyositis | Completed | 2018-12-17 | 2021-10-05 | ClinicalTrials.gov |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for P… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2018-04-25 | 2023-02-19 | ClinicalTrials.gov |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for P… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2018-04-25 | 2023-02-19 | ClinicalTrials.gov |
| NCT03451045 | Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2017-12-22 | 2020-06-17 | ClinicalTrials.gov |
| NCT03451045 | Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2017-12-22 | 2020-06-17 | ClinicalTrials.gov |
| NCT03093402 | JBT-101 in Systemic Lupus Erythematosus (SLE) | Phase2 | Systemic Lupus Erythematosus | Completed | 2017-12-21 | 2021-07-28 | ClinicalTrials.gov |
| NCT03093402 | JBT-101 in Systemic Lupus Erythematosus (SLE) | Phase2 | Systemic Lupus Erythematosus | Completed | 2017-12-21 | 2021-07-28 | ClinicalTrials.gov |
| NCT03398837 | Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemi… | Phase3 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2017-12-18 | 2020-12-21 | ClinicalTrials.gov |
| NCT03398837 | Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemi… | Phase3 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2017-12-18 | 2020-12-21 | ClinicalTrials.gov |
| NCT03237988 | Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 i… | Phase1 | Healthy Subjects | Completed | 2017-07-20 | 2017-10-04 | ClinicalTrials.gov |
| NCT03237988 | Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 i… | Phase1 | Healthy Subjects | Completed | 2017-07-20 | 2017-10-04 | ClinicalTrials.gov |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone … | Phase1 | Renal Cell Cancer | Completed | 2016-01-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone … | Phase1 | Renal Cell Cancer | Completed | 2016-01-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT02465450 | Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in … | Phase2 | Cystic Fibrosis | Completed | 2015-09-29 | 2016-12-28 | ClinicalTrials.gov |
| NCT02465450 | Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in … | Phase2 | Cystic Fibrosis | Completed | 2015-09-29 | 2016-12-28 | ClinicalTrials.gov |
| NCT02465437 | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Scl… | Phase2 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2015-08-01 | 2020-12-11 | ClinicalTrials.gov |
| NCT02465437 | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Scl… | Phase2 | Diffuse Cutaneous Systemic Sclerosis | Terminated | 2015-08-01 | 2020-12-11 | ClinicalTrials.gov |
| NCT02466243 | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Phase2 | Dermatomyositis | Terminated | 2015-06-01 | 2021-01-29 | ClinicalTrials.gov |
| NCT02466243 | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Phase2 | Dermatomyositis | Terminated | 2015-06-01 | 2021-01-29 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT02465450 |
| JBT-101 (lenabasum) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT02465450 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| JBT-101 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| JBT-101 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| Placebo oral capsule | Other | Phase PHASE3 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT03398837 |
| Lenabasum 20 mg | Other | Phase PHASE3 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT03398837 |
| Lenabasum 5 mg | Other | Phase PHASE3 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT03398837 |
| Part B Open-Label Extension | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT02465437 |
| Placebo | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT02465437 |
| JBT-101 | Other | Phase PHASE2 | Diffuse Cutaneous Systemic Sclerosis | TERMINATED | NCT02465437 |
| Placebo | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Lenabasum 5 mg | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Lenabasum 20 mg | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Placebo | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Lenabasum 5 mg | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Lenabasum 20 mg | Other | Phase PHASE3 | Dermatomyositis | COMPLETED | NCT03813160 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| JBT-101 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03451045 |
| Lenabasum 5 mg | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03451045 |
| Lenabasum 20 mg | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT03451045 |
| Placebo | Other | Phase PHASE2 | Dermatomyositis | TERMINATED | NCT02466243 |
| JBT-101 | Other | Phase PHASE2 | Dermatomyositis | TERMINATED | NCT02466243 |
| Anti-PD-1 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265727 |
| CRB-701 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265727 |
| Placebo | Other | Phase PHASE1 | Obese But Otherwise Healthy Participants | RECRUITING | NCT07310901 |
| CRB-913 | Other | Phase PHASE1 | Obese But Otherwise Healthy Participants | RECRUITING | NCT07310901 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| JBT-101 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT03093402 |
| Standard of Care | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-006 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-444 Tablets | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| CPI-444 Capsules | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| Ciforadenant + atezolizumab | Other | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| Ciforadenant | Other | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| daratumumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| Ciforadenant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| Placebo + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 1 mg/kg + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 2 mg/kg + SOC | Other | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 + pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 + ciforadenant | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-818 | Other | Phase PHASE1 | T-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT03952078 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Soquelitinib | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Placebo | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06345404 |
| Soquelitinib | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06345404 |
| Pralatrexate | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Belinostat | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Soquelitinib | Other | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Pralatrexate | DRUG | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Belinostat | DRUG | Phase PHASE3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | RECRUITING | NCT06561048 |
| Placebo | DRUG | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Soquelitinib | DRUG | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07441395 |
| Placebo + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 1 mg/kg + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| CPI-006 2 mg/kg + SOC | DRUG | Phase PHASE3 | Covid-19 | TERMINATED | NCT04734873 |
| Standard of Care | OTHER | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| daratumumab | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |
| CPI-818 | DRUG | Phase PHASE1 | T-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT03952078 |
| CPI-006 + pembrolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 + ciforadenant | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03454451 |
| CPI-006 | DRUG | Phase PHASE1 | COVID-19 | COMPLETED | NCT04464395 |
| CPI-444 Tablets | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| CPI-444 Capsules | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03237988 |
| Ciforadenant + atezolizumab | DRUG | Phase PHASE1 | Renal Cell Cancer | COMPLETED | NCT02655822 |
| Ciforadenant | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04280328 |